These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17111156)
21. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice]. Svojanovská K Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928 [TBL] [Abstract][Full Text] [Related]
22. Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures. Vujović S; Zidverc J; Stojanović M; Penezić Z; Ivović M; Dukić V; Drezgić M Gynecol Endocrinol; 2005 Nov; 21(5):243-7. PubMed ID: 16373242 [TBL] [Abstract][Full Text] [Related]
23. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. Dickerson V J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673 [TBL] [Abstract][Full Text] [Related]
24. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Mansour D Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405 [TBL] [Abstract][Full Text] [Related]
25. YAZ and the novel progestin drospirenone. Mishell DR J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044 [TBL] [Abstract][Full Text] [Related]
26. Clinical experiences with drospirenone: from reproductive to postmenopausal years. Pérez-López FR Maturitas; 2008 Jun; 60(2):78-91. PubMed ID: 18468818 [TBL] [Abstract][Full Text] [Related]
31. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Fruzzetti F; Lello S; Lazzarini V; Fratta S; Orrù M; Sorge R; Minerba L; Ricci C; Genazzani AR; Melis GB; Paoletti AM Contraception; 2007 Mar; 75(3):199-203. PubMed ID: 17303489 [TBL] [Abstract][Full Text] [Related]
32. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Ylikorkala O Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649 [No Abstract] [Full Text] [Related]
33. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M; J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453 [TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537 [TBL] [Abstract][Full Text] [Related]
35. Use of an oral contraceptive containing drospirenone in an extended regimen. Sillem M; Schneidereit R; Heithecker R; Mueck AO Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328 [TBL] [Abstract][Full Text] [Related]